Journal of Nuclear Medicine · 2018 · 170 citations · 26 references
MedicineNuclear MedicineOncologyCell TherapyMolecular ImagingTranslational OncologyChimeric Antigen Receptor T-cell TherapyImmunotherapy For Brain TumorsImmunotherapy For Solid TumorsOncologic Nuclear ImagingTargeted Imaging AgentsTumor ImagingCell Viability AssaysGlioblastoma ImagingGlioblastoma ImmunotherapyLabeling Of Cell TherapiesT Cell Cytokine ProductionT Cell CytotoxicityT-cell TherapyTumor Progression Monitoring
Chimeric antigen receptor (CAR) T cell therapy is a promising clinical approach for reducing tumor progression and prolonging patient survival. However, improvements in both the safety and the potency of CAR T cell therapy demand quantitative imaging techniques to determine the distribution of cells after adoptive transfer. The purpose of this study was to optimize <sup>89</sup>Zr-oxine labeling of CAR T cells and evaluate PET as a platform for imaging adoptively transferred CAR T cells. <b>Methods:</b> CAR T cells were labeled with 0–1.4 MBq of <sup>89</sup>Zr-oxine per 10<sup>6</sup> cells and assessed for radioactivity retention, viability, and functionality. In vivo trafficking of <sup>89</sup>Zr-oxine–labeled CAR T cells was evaluated in 2 murine xenograft tumor models: glioblastoma brain tumors with intracranially delivered IL13Rα2-targeted CAR T cells, and subcutaneous prostate tumors with intravenously delivered prostate stem cell antigen (PSCA)–targeted CAR T cells. <b>Results:</b> CAR T cells were efficiently labeled (75%) and retained more than 60% of the <sup>89</sup>Zr over 6 d. In vitro cytokine production, migration, and tumor cytotoxicity, as well as in vivo antitumor activity, were not significantly reduced when labeled with 70 kBq/10<sup>6</sup> cells. IL13Rα2-CAR T cells delivered intraventricularly were detectable by PET for at least 6 d throughout the central nervous system and within intracranial tumors. When intravenously administered, PSCA-CAR T cells also showed tumor tropism, with a 9-fold greater tumor-to-muscle ratio than for CAR-negative T cells. <b>Conclusion:</b><sup>89</sup>Zr-oxine can be used for labeling and imaging CAR T cells while maintaining cell viability and function. On the basis of these studies, we conclude that <sup>89</sup>Zr-oxine is a clinically translatable platform for real-time assessment of cell therapies.
26
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown, Darya Alizadeh, Renate Starr et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17